Burlington Stores Inc vs ClearPoint Neuro Inc — how do they compare? Burlington Stores Inc trades at $354.47 (market cap $22.26B), while ClearPoint Neuro Inc trades at $15.1 (market cap $462.44M). The key difference: Burlington Stores Inc is far larger — about 48.1× ClearPoint Neuro Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| BURL | CLPT | |
|---|---|---|
Market Cap | $22.26B | $462.44M |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $29.60 |
52-Week Low | $242.43 | $8.66 |
Enterprise Value | $27.38B | $497.03M |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $353.63, down 4.81% in the last session but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical setup with key support at $346 and resistance at $365, while fundamentals reveal impressive profitability with 39.14% ROE and expanding margins. Recent news highlights the company's successful smaller-store strategy and upward revised 2026 outlook.
BURL presents a compelling growth opportunity with 94% analyst buy ratings and a $367 consensus target offering 3.8% upside. However, elevated valuation multiples (P/E 36.92) and competitive retail pressures warrant caution. The company's debt-to-asset ratio rising to 20.99% in 2026 and recent insider selling of $619,200 worth of shares represent notable risk factors for investors.
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Trailing returns across standard periods
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →